Mometasone nasal

Rhinocort Aqua and Nasonex are preparations containing topical nasal corticosteroids (budesonide and mometasone furoate respectively). Otrivine contains a nasal decongestant (xylometazoline) and Sudafed is a systemic preparation containing a nasal decongestant (phenylephrine). Molcer is a preparation for ear-wax removal and which contains docusate sodium. Emadine contains an antihistamine (emedastine) and is presented as eye drops. 

Sofradex contains dexamethasone, framycetin and gramicidin and is indicated in otitis externa. Canesten contains clotrimazole and is indicated for fungal infections and may be used in otitis externa where a fungal infection is suspected. Nasonex contains mometasone, a corticosteroid, and is used in nasal allergy. 

Beclomethasone dipropionate, triamcinolone acetonide, budesonide, flunisolide, and mometasone furoate are available as nasal sprays for the topical treatment of allergic rhinitis. They are effective at doses (one or two sprays one, two, or three times daily) that in most patients result in plasma levels that are too low to influence adrenal function or have any other systemic effects. 

In this chapter, analysis of the excipient in Nasonex (mometasone naral spray) is used as a typical example to demonstrate how to select a proper analytical method. Nasonex Nasal Spray contains Mometasone Furoate, microcrystalline cellulose, and carboxymethylcellulose sodium NF, citric acid USP, sodium citrate USP, benzalkonium chloride solution NF, glycerin USP, polysorbate 80 NF, phenylethyl alcohol USP, and water USP. 

Nasonex nasal spray, 50 meg is a metered-dose, manual-pump spray unit containing an aqueous suspension of mometasone furoate monohydrate equivalent to 0.05% w/w mometasone furoate, calculated on the anhydrous basis, in an aqueous medium containing glycerin, micro-... 

Following IV suspension or inhalation administration, mometasone furoate was detected in the plasma for up to 8 hours, with a half-life of 4 to 6 hours (Table 33.5) and an oral bioavailability of less than 1%. It is extensively metabolized with less than 10% of the administered dose recovered in the urine unchanged (108). Among the polar metabolites ( 80%) and their conjugates (42%) that were recovered were 6(3-hydroxymometasone furoate and its 21-hydroxy metabolite. In contrast, following intranasal administration, its plasma concentrations were below the limit of quantification, and the systemic bioavailability by this route was estimated to be less than 1 %. The majority of the intranasal dose for mometasone furoate is deposited in the nasal mucosa and swallowed without absorption in the Gl tract until eliminated in the feces (approximately 50-90% of the intranasal dose is recovered in the feces). That portion of the intranasal dose that was absorbed was extensively metabolized. These results indicate that inhaled mometasone furoate has negligible systemic bioavailability and is extensively metabolized, with reduced risk for causing systemic adrenal suppression effects. 

Mometasone furoate nasal suspension is supplied as an aqueous suspension with an atomizing pump that dispenses 50 pg per metered spray. The total daily dose for mometasone furoate is 200 pg. 

Nasal suspensions can be characterised by thixotropic properties [41]. Nasal sprays containing triamcinolone acetonide or mometasone furoate showed time-dependent, reversible loss of viscosity under shear (shaking or spraying,) flowing more freely. Recovery of viscosity after application is likely to inhibit suspension flowing out from the nasal cavity [42, 43]. 

---